ArticlePDF Available

Review : Role of Galactooligosaccharides as Prebiotic

Authors:
  • Mehsana Urban Institute of Science, Ganpat University, Mehsana, Gujarat, India

Abstract

Specific types of dietary carbohydrates, viz. Non-digestible oligosaccharides (NDOs), are known to pass through upper GI tract in intact or non-digestible form and promote the growth of beneficial bacteria in the colon. The acceleration of the industrial production of NDOs since the 1970s has mainly been achieved. Ability of galactooligosaccharide (GOS) to resists digestion and absorption in the small intestine and reaches the cecum and colon, where it is fermented by colonic bacteria. Because of bifidogenic nature and immuno-modulatory properties, GOS along with probiotics can ferment short chain fatty acids (SCFA) and gases, which is effective in genotoxicity, lowering cholesterol, improving infant health and efficient in diseases.
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 15
http://www.themicrobes.net
Review : Role of Galactooligosaccharides as Prebiotic
M. N. Hingu,1 H.S.Shah,2
Dairy Science College, Amreli1, Gujarat, India
Department of Microbiology, Shri A. N. Patel P. G. Institute, Anand2, Gujarat, India
Email (Corresponding Author1):- hingumitesh@gmail.com
Abstract:
Specific types of dietary carbohydrates, viz. Non-digestible oligosaccharides (NDOs), are
known to pass through upper GI tract in intact or non-digestible form and promote the growth of
beneficial bacteria in the colon. The acceleration of the industrial production of NDOs since the
1970s has mainly been achieved. Ability of galactooligosaccharide (GOS) to resists digestion and
absorption in the small intestine and reaches the cecum and colon, where it is fermented by
colonic bacteria. Because of bifidogenic nature and immuno-modulatory properties, GOS along
with probiotics can ferment short chain fatty acids (SCFA) and gases, which is effective in
genotoxicity, lowering cholesterol, improving infant health and efficient in diseases.
Keywords: Galactooligosaccharide (GOS), Prebiotic, Probiotic, Non digestible oligosaccharides
1. Introduction:
The term “prebiotic” was coined by Prof. Glenn Gibson and Prof. Marcel Roberfroid in
1995 and defined it as a “non-digestible food ingredient that beneficially affects the host by
selectively stimulating the growth and/or activity of one or a limited number of bacteria in the
colon, and thus improves host health” (Gibson and Roberfroid, 1995). Specific types of dietary
carbohydrates, viz. non-digestible oligosaccharides (NDOs), are known to pass through upper GI
tract in intact or non-digestible form and promote the growth of beneficial bacteria in the colon,
and are thus recognized as Prebiotics (Fuller and Gibson, 1997). Milk is a classical natural
example of a prebiotic diet of mammals during infancy. The galactooligosaccharides (GOS)
present in milk, are the most relevant component for the prebiotic effect of human milk (Kunz et
al., 2000; Boehm and Stahl, 2007). As an alternative to probiotics, prebiotics can also modulate
the gut microbiota (Bhatia and Rani, 2007). Both popular concepts target the gastrointestinal
microbiota (Venter, 2007).
2. Production and charecterization of NDOs:
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 16
http://www.themicrobes.net
Recent data on GOS production are not available. However, the market for prebiotics in food
is growing rapidly. A 2007 report on the world prebiotic market states that there are over 400
prebiotic food products and more than 20 companies producing oligosaccharides and fibres used
as prebiotics [http://www.ubic-consulting.com/template/fs/The-World-Prebiotic-Ingredient-
Market.pdf]. A Frost & Sullivan review reported that the European prebiotics market is currently
worth €87 million, and will reach €179.7 million by 2010. Global sales were approximately $1
billion USD in 2011; and GIA (Global Industry Analyst) predicts that figure will quintuple by
2018 (http://www.foodproductiondaily.com/Financial/Prebiotics-market-to-hit-4.8-billion-by-
2018).
The acceleration of the industrial production of NDOs since the 1970s has mainly been
achieved by the development of downstream processes using enzymatic and chemical reactions.
Today, over 20 different types of NDOs are on the world market, which are either extracted from
natural sources (e.g. raffinose and soybean oligosaccharides), obtained by the enzymatic
hydrolysis of polysaccharides (e.g. xylooligosaccharides and isomaltooligosaccharides), or
produced by enzymatic transglycosylation (e.g. GOS, and fructooligosaccharides-FOS). The most
abundantly supplied and utilized group of NDOs as food ingredients are GOS and FOS, which are
generally produced by enzymatic transglycosylation because of adequate supply of the raw
materials and the high efficiency of the reaction (Sako et al., 1999).
3. Galactooligosaccharides (GOS)
3.1. Technolgical Characteristics of Galactooligosaccharides
3.1.1 Production:
Galactose containing oligosaccharides of the form Glu α 1-4[β Gal 1-6]n where n=2-5, are
termed galactooligosaccharides and are present in both human as well as cow milk (Tuohy et al.,
2005). GOS is produced from lactose by the action of β-galactosidases having
transgalactosylation activity (Akiyama et al., 2001; Aslan and Tanrıseven, 2007) and the GOS
production can be enhanced by mixing glucose oxidase and β-galactosidase (Cheng-Chao et al.,
2006). One or more d-galactosyl units onto the D-galactose moiety of lactose used to produce
GOS by βgalactosidases during the hydrolysis of βgalactoside linkage of lactose (Moller et al.,
2001). The linkage between the galactose units, the efficiency of transgalactosylation, and the
components in the final products depend on the enzymes and the conditions used in the reaction
(Van Laere et al., 2000). The β -galactosidases used in different experiments are derived from
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 17
http://www.themicrobes.net
various microbes viz. Bacillus circulans (Mozaffar et al., 1984), Bifidobacterium bifidum (Goulas
et al., 2007), Escherichia coli (Chen et al., 2003), Bullera singularis (Shin et al., 1998) and
Archaeon Sulfolobus solfataricus (Splechtna et al., 2001). Thermostable or immobilized β-
galactosidase is generally used to increase the production of GOS (Smart, 1991 and Cheng et al.,
2006). Goulas and co-workers (2007) reported that the toluene treated whole cells of
Bifidobacterium bifidum NCIMB 41171 showed better GOS conversion from lactose (80-85%).
3.1.2 Physiological characteristics:
Commercially available GOS are mixtures of several molecular species of
oligosaccharides (more than 55%), lactose (~20%), glucose (~20%), and a small amount of
galactose. GOS are available in liquid and powder forms (Voragen, 1998).
4. Effect of Galactooligosaccharides (GOS) on human health
4.1 Indigestibility and Energy Value
GOS having β -configuration, whereas human gastrointestinal digestive enzymes are
mostly specific for α-glycosidic bonds and the activity of β-galactosidase localized at the brush
border membrane of the small intestine, which has the potential to digest GOS, is usually weak or
often deficient (Ito and Kimura, 1993), so it resists digestion and absorption in the small intestine
and reaches the cecum and colon, where it is fermented by colonic bacteria (Ishikawa et al.,
1995). The indigestibility of GOS in vivo has been demonstrated by means of the hydrogen breath
test (Tanaka et al., 1983; Ishikawa et al., 1995). According to the standardized method developed
in Japan (Oku, 1996), the caloric value of GOS is 1.73 kcal g-1 (Watanuki et al., 1996).
4.2 Effect of GOS on intestinal microbial ecology and host
4. 2. 1 Utilization of 4’-galactosyllactose by intestinal bacteria in vitro:
Bacteria which inhabit the large intestine may have acquired divergent glycolytic activities
to efficiently utilize non-digestible carbohydrates which are abundant in the colon (Iino and
Morishita, 1990). GOS can be fermented by some strains of intestinal Bifidobacteria,
Lactobacillus, Bacteroides, and Clostridium (Tanaka et al., 1983; Ishikawa et al., 1995;
Matsumoto, 1990).
4. 2. 2 Effects of indigestion on intestinal microflora
(i) Bifidogenic activity:
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 18
http://www.themicrobes.net
GOS is bifidogenic in nature (Olano-Martin et al., 2002) and also effective at increasing
numbers of Bifidobacteria (Ito et al., 1990; Bouhnik et al., 1997, 1999 and 2007; Djouzi and
Andlueux, 1997; Rivero and Santamaría, 2001; Tzortzis et al., 2005; Macfarlane et al., 2006 and
Depeint et. al., 2013) and lactate whilst generating the least gas (Rycroft et al., 2001), which
exchanges the predominant bacteria in the healthy adult human intestine along with reduction in
breath hydrogen (Bouhnik et al., 1997).
(ii) Metabolism in the colon
Oligosaccharides may directly inhibit infections by enteric pathogens due to their ability to
act as structural mimics of the pathogen binding sites that coat the surface of GI epithelial cells
(Shoaf et al., 2006), also change the composition of the mucosa associated flora significantly
(Langlands et al., 2004), hence the effectiveness of a prebiotic depends on its ability to be
selectively fermented by and to support growth of specific targeted organisms (Huebner et al.,
2007). The end products of fermentation of carbohydrates by colonic bacteria are short chain fatty
acids (SCFA) and gases (Bouhnik et al., 1997; Pereira et al., 2003). The in vitro fermentation of
GOS showed highest decrease in numbers of Clostridia and higher amount of SCFAs (Rycroft et
al., 2001). In another study, GOS and other prebiotics reduced the adherence Enteropathogenic
Escherichia coli on tissue culture cells (Shoaf et al., 2006). It is having laxative effect too (Alles
et al., 1996).
4. 2. 3 Physiological effects of Galactooligosaccharides (GOS)
(i) Improvement of Defecation and Elimination of Ammonia:
GOS showed improved defecation (Deguchi et al., 1997) and the SCFA production
contributed by increasing osmotic pressure and stimulating peristalsis (Ishikawa et al., 1995).
Bifidobacteria have the ability to assimilate ammonia as a nitrogen source, hence it reduces the
blood ammonia and suppress the ammonia-producing bacteria. The assimilation of amino acids by
intestinal bacteria yields also SCFA and/or branched- chain fatty acids as well as ammonia as
fermentation products (Deguchi et al., 1993; Mwenya et al., 2005).
(II) Stimulation of Mineral Absorption and Bone Mineralization:
GOS stimulates the calcium and magnesium absorption, which takes place in both the
small and large intestines, and accompanied by a reduction in cecal pH and increase in cecal and
cecal digesta weight (Chonan and Watanuki, 1995). GOS when fed to rats (Chonan et al., 2001),
postmenopausal women (van den Heuvel et al., 2000) and young male volunteers (van den
Heuval et al., 1998) showed increased calcium, magnesium and iron absorption. It was shown that
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 19
http://www.themicrobes.net
prebiotics stimulated the absorption of iron and of bone-relevant minerals such as calcium,
magnesium, and zinc in short-term experiments and improved bone mineral content in the long-
term perspective (Abrahms et al. 2005; Scholz-Ahrens et al., 2007). Trinidad and co-workers
(1996) demonstrated that acetic acid and propionic acid when introduced into the six human
volunteers distal colon directly; increased calcium disappearance in the colon.
(iii) Effect on Bacterial enzyme activities associated with genotoxicity and cancer:
Several bacterial enzymes, such as β-glucuronidase, β-glucosidase, and nitroreductase may
play a role in colon carcinogenesis by converting pre-carcinogens to proximal carcinogens
(Rowland, 1988). In human studies, Ishikawa et al., (1995) detected a decreasing tendency in
fecal β-glucuronidase activity at a dose of 10 g GOS per day. GOS (10%, w/w) was associated
with decreases in β-glucuronidase activity and secondary bile acid and increased β-galactosidase
concentrations in feces of human flora-associated rats (Kikuchi et al., 1996). The daily intake of
15 g of GOS in young healthy volunteers resulted in a significant increase in fecal acetate and a
significant decrease in fecal β-glucuronidase activity (van Dokkum et al., 1999). In vitro studies
using a three-stage continuous culture of the large gut (McBain and Macfarlane, 2001) indicated
that 5% GOS (85% pure), strongly suppressed bacterial synthesis of arylsulphatase, β-glucosidase
and β-glucuronidase in all three culture vessels. Butyrate also play an important role in preventing
cancer (Topping and Clifton, 2001).
(iv) Effect on cholesterol and lipid metabolism:
The hypotriglyceridemic and Hypocholesterolemic effects of NDOs may be attributable to
the reduction of hepatic synthesis and/or absorption of triglycerides and cholesterol (Kok et al.,
1996). The mechanisms by which dietary carbohydrates elicit their lipid-lowering effects are,
however, still a matter of debate. Limited numbers of reports are available which indicate positive
effects of GOS on serum cholesterol metabolism in human subjects. Chonan et al., (1995)
reported increase in LDL cholesterol and triglycerides with a striking reduction in HDL
cholesterol after consumption of GOS in postmenopausal status of the rats.
(v) Neonates and infants:
Babies provide a unique opportunity to investigate the effects of prebiotics on the gut
microbiota, as they are born with what is an essentially sterile GI tract. For the first 2 years of life,
bifidobacteria predominate in the colonic microbiota in breast-fed infants, constituting up to 95%
of culturable bacteria (Tissier, 1900 and 1906; Bullen and Willis, 1971). The majority of trials
have focused on demonstrating the abilities of oligosaccharides to increase faecal bifidobacteria
populations (Moro and Arslanoglu, 2005), and relatively few studies have been made on disease
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 20
http://www.themicrobes.net
prevention and on hypersensitivity response. GOS alone or along with probiotics showed
reduction in eczema, atopic eczema, diarrhoea and dysentery (Sazwal et al., 2004) as well as IgE
associated disease (Kukkonen et al., 2007). Despite a few studies at present, the failure to find a
satisfactory mechanism of action implies that more investigations will be needed before prebiotics
can begin to play a role in the routine management of atopic disease (Macfarlane et al,. 2008).
Bakker-Zierikzee et al., (2005), fed the prebiotic mixture of GOS/FOS (0.6%) to 19 infants,
showed higher faecal acetate contentand also resulted in a similar effect on metabolic activity of
the flora as in breast-fed infants.
(vi) Effects on diseases:
Obesity and diet have long been linked to atherosclerosis, cardiovascular disease, type 2
diabetes (Wong et al., 1989; Singh et al., 1992), rheumatoid arthritis (Feldmann et al., 1996) and
in some inflammatory diseases (Gross et al., 1992; Woywodt et al. 1999). GOS shows dose-
dependent benefits in erythema and swelling of limbs, as well as histological findings in the hind
paw joints (Abe et al., 2004). Song and his co-workers (2013), found that GOS and GOS-rich
prebiotic yogurt when administered to SOD1G93A mice, showed significant delay in the disease
Amyotrophic lateral sclerosis (ALS) onset and prolonged the lifespan in SOD1G93A mice and also,
these products increased the concentration of folate, VitB12. Trans-galactooligosaccharide
significantly enhanced faecal bifidobacteria (3.5 g/d P < 0.005; 7 g/d P < 0.001) (Silk D. B. et. al.
2009).
4. 2. 4 Immunomodulatory Properties
(i) Prebiotics and immune system:
Immunity comprises both innate and adaptive responses (Albers et al., 2005). The gut
contains a major part of the body‟s immune system, termed the gut-associated lymphoid tissue
(GALT). To date, few studies have been made on interactions between fermentable carbohydrates
and the immune system, or whether they exert direct or indirect modulatory effects. Schley and
Field (2002) reviewed immunological effects that have been observed after adding prebiotics to
the diet of dogs/mice/rats. The effects includes increase in mucosal immunoglobulin production,
mesenteric lymph nodes, Peyer‟s patches, and altered cytokine formation and lymphocyte
numbers in the spleen and intestinal mucosa. In the conclusion they suggested that the methods by
which prebiotics can exert their effects on the immune system, and attenuate inflammation in the
colon, include increased SCFA production and increases in immunogenic bacteria such as
lactobacilli and bifidobacteria. The SCFAs stimulates apoptosis (Rowland, 1988) and may be a
protective factor in carcinogenesis (Scheppach and Weiler 2004), propionate has been shown to
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 21
http://www.themicrobes.net
be anti-inflammatory with respect to colon cancer cells (Nurmi et al., 2005). Glutamine is used by
immune cells in the body and increased production of butyrate may reduce the requirement of
epithelial cells in the gut for this amino acid, thereby enhancing immune system reactivity
(Jenkins et al., 1999). Administration of galactooligosaccharide mixture [Bi2muno (B-GOS)] to
overweight adults (n=45) showed positive effects on the composition of the gut microbiota, the
immune response, and insulin, total cholesterol, and trans- galactooligosaccharide concentrations
(Vulveic et. al., 2013). They have also mentioned that B-GOS may be a useful candidate for the
enhancement of gastrointestinal health, immune function, and the reduction of metabolic
syndrome risk factors in overweight adults.
(ii) The mucosal immune system:
Bakker-Zierikzee et al., (2006), fed the prebiotic mixture of GOS/FOS (0.6%) to 19
infants, which showed higher faecal SIgA level in the body. In another study (Scholtens et al.,
2008) 215 infants were fed GOS/FOS containing formula and they also found the higher level of
SIgA in the body. The intestinal mucosa contains large amounts of sIgA which has a protective
role against adherence and invasion by harmful bacteria and viruses (Yasui et al., 1991).
(iii) Allergy:
Allergic diseases are associated foods and environmental substances (Ozaki et al., 2007).
Atopic dermatitis (AD) is one of the early signs of allergy in infancy, and can affect 1025% of
children in Western countries and prebiotics shows the beneficial effects on the same (Moro et al.,
2006). In one study, infants (n =461) with high risk of allergy, when fed with GOS alond with
probiotics showed significant reduction in eczema and atopic eczema (Kukkonen et al., 2007).
Administration of GOS reduced the allergic airway eosinophilia in ovalbumin-sensitizedbrown
Norway rats (Sonoyama et al., 2005).
(iv) Inflammatory bowel diseases (IBD):
Ulcerative colitis (UC) and Crohn‟s disease (CD) are both inflammatory conditions that
are thought to result from inappropriate immune responses to the normal commensal gut
microbiota (Cummings et al., 2003). Mucosa-associated lymphoid tissue normally maintains gut
integrity by tightly regulating immune responses to commensal and pathogenic bacteria and
dietary antigens, by a balance of pro-inflammatory and anti-inflammatory cytokines. Studies
involving the use of prebiotics in human IBD are distinctly lacking (Cummings et al., 2003;
Macfarlane et al., 2004). In one report by Holma et al., (2002), rats were fed 4 g kg -1 body mass
of either whey or lactose-derived GOS per day shows increase in bifidobacterial numbers in the
animals, there was no reduction in inflammatory processes.
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 22
http://www.themicrobes.net
5. Applications of Galactooligosaccharides (GOS) as food ingredients
In the 1980s, consumers' demand for healthy foods led to a dramatic increase in the
development of NDO-containing foods. Low carcinogenicity, low calorific values, and low
sweetness were the most important characteristics of these oligosaccharides which show
beneficial effects on human health. At the same time, NDOs generally have preferable
physicochemical characteristics applicable to various processed foods, fermented milk products,
breads, jams, confectionery, beverages, also used in baby foods and specialized foods for elderly
and hospitalized people. In particular, the stability of GOS in acidic and high-temperature
conditions enable GOS to be applied without decomposition in a wider variety of foods
(Macfarlane et al., 2008).
6. Safety aspects
GOS have a generally recognized as safe (GRAS) status due to the fact that they are
components of human milk and traditional yoghurt and they are produced from ingested lactose
by resident intestinal bacteria which produce β -galactosidase. It is non toxic and non mutagenic.
The only adverse effect of GOS known so far is transient diarrhoea due to the so-called „osmotic
diarrhoea', which occurs when excess GOS are consumed (Macfarlane et al., 2008).
7. New vision in the future prospects of GOS : Conclusion
Recent advances in the research of the intestinal microflora clarify the importance of host
microbial interaction for human health. The prebiotic concept borne from the preferential growth
stimulating activity of food components on specific types of colonic bacteria is being accepted
from a scientific point of view as well as from a consumer point of view. NDOs including GOS
are recognized as bifidogenic factors. However, much still should have to be clarified about the
intestinal microflora and host microbe interaction. Modern biotechnology techniques such as
detection and identification methods, molecular dissection of bacteria, and in vitro cell culture
methods will promote a better understanding of the role of NDOs and intestinal bacteria. GOS
seem to have several unique characteristics which enable manufactures to utilize GOS in various
foods. Scientific substantiation of the biological effects is necessary to make this a reality
(Macfarlane et al., 2008).
References:
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 23
http://www.themicrobes.net
1. Abe C, Fujita K, Kikuchi E, Hirano S, Kuboki H, Yamashita A, Hashimoto H, Mori S. et
al. (2004). Int. J. Tiss. React. 26: 6573. Cited from Macfarlane G T, Steed H and
Macfarlane S. (2008). J. Appl. Microbiol. 104: 305-344.
2. Abrams S A, Griffin I J, Hawthorne K M, Liang L, Gunn S K, Darlington G and Ellis K J.
(2005). Am. J. Clin. Nutr. 82: 471 476.
3. Akiyama K, Takase M, Horikoshi K and Okonogi S. (2001). Biosci. Biotechnol. Biochem.
65: 438441.
4. Albers R, Antoine J M, Bourdet S R, Calder P C, Gleeson M, Lesourd B, Samartın S,
Sanderson I R, Loo J V, Dias F W V and Watzl B. (2005). Br. J Nutr. 94: 452481.
5. Alles M S., Hautvasti J G. A. J., Nagengast F M. , Hartemink R, Van Laere K M. J. and
Jansen J B M J. (1996). Br. J Nutr. 76: 211-221.
6. Aslan Y and Tanrıseven A. (2007). J. Mol. Catal. B: Enzym. 45: 7377.
7. Bakker-Zierikzee A M, Alles M S, Knol J, Kok F J, Tolboom J J and Bindels J G. (2005).
Br. J. Nutr. 94:783-90. .
8. Bakker-Zierikzee A M, van Tol E A F, Kroes H, Alles M S, Kok F J and Bindels J G.
(2006). Pediatr. Allerg. Immunol. 17: 134140.
9. Bhatia A and Rani U. (2007). J. Clin. Diagn. Res. 1: 546-554.
10. Boehm G and Stahl B. (2007). J. Nutr. 137: 847S 849S.
11. Bouhnik Y, Flourie´ B, D‟Agay-Abensour L, Pochart P, Granet G, Durand M and
Rambaud J C. (1997). J Nutr. 127: 444448.
12. Bouhnik Y, Raskine L, Champion K, Andrieux C, Penven S, Jacobs H and Simoneau G.
(2007). Nutr. Res. 27: 187 193.
13. Bouhnik Y, Vahedi K, Achour L, Attar A, Salfati J, Pochart P, Marteau P, Flourie B,
Bornet F and Rambaud J C. (1999). J. Nutr. 129: 113116.
14. Bullen C L and Willis A T. (1971). BMJ. 3: 338343. Cited from Macfarlane G T, Steed
H and Macfarlane S. (2008). J. Appl. Microbiol. 104: 305 - 344.
15. Chen C. W, Yang C C O and Yeh C W. (2003). Enzyme Microb. Technol. 33: 497507.
16. Cheng T C, Duan K J and Sheu D C. (2006). J. Chem. Technol. Biotechnol. 81: 233236.
17. Cheng-Chao C, Yu M C, Cheng T C, Sheu D C, Duan K J and Tai W L. (2006).
Biotechnol. Lett. 28: 793-797.
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 24
http://www.themicrobes.net
18. Chonan O and Watanuki M. (1995). J. Nutr. Sci. Vitaminol (Tokyo). 41: 95-104. Cited
from Sako T, Keisuke M and Ryuichiro T. (1999). Int. Dairy. J. 9: 69-80.
19. Chonan O, Matsumoto K and Watanuki M. (1995). Biosci. Biotechnol. Biochem. 59: 236
239.
20. Chonan O, Takahashi R and Watanuki M. (2001). Biosci. Biotechnol. Biochem. 65: 1872
1875.
21. Cummings J H, Macfarlane G T and Macfarlane S. (2003). Curr. Iss. Intest. Microbiol. 4:
920. Cited from Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl. Microbiol.
104: 305 - 344.
22. Deguchi Y, Makino A, Iwabuchi A, Watanuki M and Yamashita T. (1993). Microb. Ecol.
Hlth. Dis. 6: 85-94.
23. Deguchi Y, Matsumoto K, Ito T and Watanuki M. (1997). Jpn. J. Nutr. 55: 13-22. (In
Japanese). Cited from Sako T, Keisuke M and Ryuichiro T. (1999). Int. Dairy J. 9: 69-80.
24. Depeint F, Tzortzis G, Vulveic J, I‟Anson K and Gibson G. R. (2013). Prebiotic
evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity
ofBifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind,
crossover, placebo-controlled intervention study. Am. J. Clin. Nutr. 87(3): 785-791.
25. Djouzi Z and Andlueux C. (1997). Br. J Nutr. 78: 313-324.
26. Feldmann M, Brennan F M and Maini R N. (1996). Ann. Rev. Immunol. 14: 397440.
Cited from Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl. Microbiol. 104:
305-344.
27. Fuller R and Gibson G R. (1997). Scand. J. Gastroenterol. 222: 28-31.
28. Gibson G R and Roberfroid M B. (1995). J. Nutr. 125: 1401-1412.
29. Goulas A, Tzortzis G and Gibson G R. (2007). Int. Dairy J. 17: 648656.
30. Gross V, Andus T, Caesar I and Roth M. (1992) Gastroenterology. 102: 514519. Cited
from Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl. Microbiol. 104: 305 -
344.
31. Holma R, Juvonen P, Asmawi M Z, Vapaatalo H and Korpela R. (2002). Scand. J.
Gastroenterol. 37: 10421047. Cited from Macfarlane G T, Steed H and Macfarlane S.
(2008). J. Appl. Microbiol. 104: 305-344.
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 25
http://www.themicrobes.net
32. http://www.foodproductiondaily.com/Financial/Prebiotics-market-to-hit-4.8-billion-by-
2018
33. http://www.ubic-consulting.com/template/fs/The-World-Prebiotic-Ingredient-Market.pdf
cited by FAO Technical Meeting on Prebiotics, September 15-16, 2007
34. Huebner J, Wehling R L and Hutkins R W. (2007). Int. Dairy J. 17: 770775.
35. Iino T and Morishita T. (1990). FEMS Microbiology Reviews. 87: 21. Cited from Sako T,
Keisuke M and Ryuichiro T. (1999). Int. Dairy J. 9: 69-80.
36. Ishikawa F, Takayama H, Matsumoto K, Ito M, Chonan O, Deguchi Y, Kikuchi-
Hayakawa H and Watanuki M. (1995). Bifdus. 9: 5-18. (in Japanese). Cited from Sako T,
Keisuke M and Ryuichiro T. (1999). Int. Dairy J. 9: 69-80.
37. Ito M and Kimura M. (1993). Microb. Ecol. Hlth. Dis. 6: 73-76. Cited from Sako T,
Keisuke M and Ryuichiro T. (1999). Int. Dairy J. 9: 69-80.
38. Ito M, Deguchi Y, Miyamori A, Matsumoto K, Kikuchi H, Matsumoto K, Kobayashi Y,
Yajima T and Kan T. (1990). Microb. Ecol. Hlth. Dis. 3: 285-292.
39. Jenkins D J A, Kendall C W C and Vuksan V. (1999). J. Nutr. 129: 1431S1433S.
40. Kikuchi H, Andrieux C, Riottot M, Bensaada M, Popot F, Beaumatin P and Szylit O.
(1996). J. Appl. Bacteriol. 80: 439-446.
41. Kok N, Roberfroid M, Robert A and Delzenne N. (1996). Br. J. Nutr. 76: 881890. Cited
from Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl. Microbiol. 104: 305-
344.
42. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Turre
T and Kuitunen M. (2007). J. Allerg. Clin. Immunol. 119: 192198.
43. Kunz C, Rudloff S, Baier W, Klein N and Strobel S. (2000). Annu. Rev. Nutr. 20: 699
722.
44. Langlands S J, Hopkins M J, Coleman N and Cummings J H. (2004). Gut. 53: 1610-1616
45. Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl. Microbiol. 104: 305-344.
46. Macfarlane S, Furrie E, Cummings J H and Macfarlane G T. (2004). Clin. Infect. Dis. 38:
16901699. Cited from Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl.
Microbiol. 104: 305-344.
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 26
http://www.themicrobes.net
47. Macfarlane S, Macfarlane G T and Cummings J H. (2006). Aliment. Pharmacol. Ther. 24:
701714.
48. Matsumoto K, Kobayashi Y, Ueyama S, Watanabe T, Tanaka R, Kan T, Kuroda A and
Sumihara Y. (1990). Galactooligosaccharides. In T. Nakanuki, Japanese Technology
Reviews (pp. 90-106). Tokyo: Gordon and Breach Science Publishers. Cited from Sako T,
Keisuke M and Ryuichiro T. (1999). Int. Dairy J. 9: 69-80.
49. Mc Bain A J and Macfarlane G T. (2001). J. Med. Microbiol. 50: 833842.
50. McIntyre A, Gibson P R and Young G P. (1993). Gut. 34: 386-391
51. Moller P L, Jorgensen F, Hansen O C, Madsen S M and Stougaard P. (2001). Appl.
Environ. Microbiol. 67: 22762283.
52. Moro G E and Arslanoglu S. (2005). Acta. Paediatrica. 94: 1417.
53. Moro G, Arslanoglu S, Stahl B, Jelinek J, Wahn U and Boehm G. (2006). Arch. Dis.
Child. 91:814819.
54. Mozaffar Z, Nakanishi K and Matsuno R. (1984). Agric. Biol. Chern., 48: 3053-3061.
55. Mwenya B, Sar C, Santoso B., KobayashiT, MorikawaR, Takaura K, Umetsu K, Kogawa
S, Kimura K, Mizukoshi H and Takahashi J. (2005). Anim. Feed Sci. Tech. 118: 1930.
56. Nurmi J, Puolakkainen P and Rautonen N. (2005). Nutr. Can. 51: 8392. Cited from
Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl. Microbiol. 104: 305-344.
57. Oku T. (1996). Jpn. J. Nutr. 54: 143-150 (in Japanese). Cited from Sako T, Keisuke M and
Ryuichiro T. (1999). Int. Dairy J. 9: 69-80.
58. Olano-Martin E, Gibson G R and Rastall R A. (2002). J. Appl. Microbiol. 93: 505511.
59. Ozaki K, Fujii S and Hayashi M. (2007). J. Health Sci. 53: 766-770.
60. Ozawa O, Ohtsuka K, and Uchida R. (1989). Nippon Shokuhin Kogyo Gakkaishi. 36: 898-
902. (In Japanese). Cited from Sako T, Keisuke M and Ryuichiro T. (1999). Int. Dairy J.
9: 69-80.
61. Pereira D I A, McCartney A L and Gibson G R. (2003). Appl. Environ. Microbiol. 69:
47434752.
62. Rivero U M and Santamaría O A. (2001). Hum. Dev. 65: 43-52.
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 27
http://www.themicrobes.net
63. Rowland I R. ed. (1998). Role of the Gut Flora in Toxicity and Cancer. London:
Academic Press. Cited from Sako T, Keisuke M and Ryuichiro T. (1999). Int. Dairy J. 9:
69-80.
64. Rowland, I. (1988). Toxicological Pathology. 16: 147-153.
65. Rycroft C E, Jones M R, Gibson G R and Rastall R A. (2001). J. Appl. Microbiol. 91: 878-
887.
66. Sako S, Keisuke M and Ryuichiro T. (1999). Int. Dairy J. 9: 69-80.
67. Santoso B, Mwenya B, Sar C, Gamo Y, Kobayashi T, Morikawa R, Kimura K, Mizukoshi
H and Takahashi J. (2004). Livest. Prod. Sci. 91: 209217.
68. Sazawal S, Dhingra U, Sarkar A, Dhingra P, Deb S, Marwah D, Menon V P and Kumar J.
et al. (2004). Asia. Pac. J. Clin. Nutr. 13: 28. Cited from Macfarlane G T, Steed H and
Macfarlane S. (2008). J. Appl. Microbiol. 104: 305-344.
69. Scheppach W and Weiler F. (2004). Curr. Opin. Clin. Nutr. Metab. Care. 7: 563567.
Cited from Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl. Microbiol. 104:
305-344.
70. Schley P D and Field C J. (2002). Br. J. Nutr. 87: S221S230.
71. Scholtens P A M J, Alliet P, Raes M, Alles M S, Kroes H, Boehm G, Knippels L M J,
Knol J and Vandenplas Y. (2008). J. Nutr. 138: 1141-1147.
72. Scholz-Ahrens K E, Ade P, Marten B, Weber P, Timm W, Açil Y, Glüer C C and
Schrezenmeir J. (2007). J. Nutr. 137: 838S846S.
73. Shin H J, Park J M and Yang J W. (1998). Process Biochem. 33: 787792.
74. Shoaf K, Mulvey G L, Armstrong G D and Hutkins R W. (2006). Infect. Immun. 74:
69206928.
75. Silk D B, Davis A, Vulevic J, Tzortzis G and Gibson G R. (2009). Clinical trial: the
effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in
irritable bowel syndrome. Aliment Pharmacol. 29(5): 508-18.
76. Singh R B, Rastogi S S, Verma R, Laxmi B, Singh R, Ghosh S and Niaz M A. (1992). Br.
Med. J. 304: 10151019. Cited from Macfarlane G T, Steed H and Macfarlane S. (2008).
J. Appl. Microbiol. 104: 305-344.
77. Smart J B. (1991). Appl. Microbiol. Biotechnol. 34: 495501.
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 28
http://www.themicrobes.net
78. Song L, Gao Y, Zhang X and Le w. (2013). Galactooligosaccharide improves the animal
survival and alleviates motor neuron death in SOD1G93A mouse model of amyotrophic
lateral sclerosis. Neuroscience. 246: 281-290.
79. Sonoyama K, Watanabe H, Watanabe J, Yamaguchi N, Yamashita A, Hashimoto H,
Kishino E, Fujita K, Okada M, Mori S, Kitahata S and Kawabata J. (2005). J. Nutr. 135:
538543.
80. Splechtna B, Petzelbauer I, Baminger U, Haltrich D, Kulbe K D and Nidetzky B. (2001).
Enzyme Microb. Technol. 29: 434440.
81. Tanaka R, Takayama H, Morotomi M, Kuroshima T, Ueyama S, Matsumoto K, Kuroda A
and Mutai M. (1983). Bifidobacteria and Microflora. 2: 17-24. Cited from Sako T,
Keisuke M and Ryuichiro T. (1999). Int. Dairy J. 9: 69-80.
82. Tissier H. (1900). Recherches sur la flore intestinale des nourissons (etat normal et
pathologique). Paris Theses: University of Paris School of Medicine. Cited from
Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl. Microbiol. 104: 305-344.
83. Tissier H. (1906). Crit. Rev. Soc. Biol. 60: 359361. Cited from Macfarlane G T, Steed H
and Macfarlane S. (2008). J. Appl. Microbiol. 104: 305-344.
84. Topping D L and Clifton P M. (2001). Physiol. Rev. 81:1031-1064.
85. Trinidad P T, Wolever T M S and Thompson L U. (1996). Am. J. Clin. Nutr. 63: 574-578.
86. Tuohy K M, Rouzaud G C M, Brück W M and Gibson G R. (2005). Curr. Pharmaceut.
Des. 11: 75-90.
87. Tzortzis G, Goulas A K, Gee J M and Gibson G R. (2005). J. Nutr. 135: 17261731.
88. van den Heuvel E G H M, Schaafsma G, Murs T and van Dokkum W. (1998). Am. J. Clin.
Nutr. 67: 445-451.
89. van den Heuvel E G H M, Schoterman M H C and Muijs T. (2000). J. Nutr. 130: 2938
2942.
90. van Dokkum W, Wezendonk B, Srikumar T S and van den Heuvel E G H M. (1999). Eur.
J. Clin. Nutr. 53: 1-7. Cited from Sako T, Keisuke M and Ryuichiro T. (1999). Int. Dairy
J. 9: 69-80.
91. Van Laere K M J, T Abee, Schols H A, Beldman G and Voragen G J. (2000). Appl.
Environ. Microbiol. 66: 13791384.
The Microbes Volume: 5, November-2013 ISSN: 2321-3728 (Online)
Page | 29
http://www.themicrobes.net
92. Venter C S. (2007). Journal of Family Ecology and Consumer Sciences. 35: 17-25.
93. Voragen A G J. (1998). Trends Food Sci. Tech. 9: 328-335.
94. Vulveic J, Juric A, Tzortzis G and Gibson G. R. (2013). A Mixture of trans-
Galactooligosaccharides Reduces Markers of Metabolic Syndrome and Modulates the
Fecal Microbiota and Immune Function of Overweight Adults. J. Nutr. doi: 10.3945/
jn.112.166132.
95. Watanuki M, Wada Y and Matsumoto K. (1996). Digestibility and physiological heat of
combustions of β 1-4 and β 1-6 galacto-oligosaccharides in vitro. Annual Reports of the
Yakult Central Institute for Microbiological Research. 16: 1-12. (In Japanese). Cited from
Sako T, Keisuke M and Ryuichiro T. (1999). Int. Dairy J. 9: 69-80.
96. Wong N D, Cupples L A, Ostfeld A M, Levy D and Kannel W B. (1989). Am. J.
Epidemiol. 130: 469480.
97. Woywodt A, Ludwig D and Neustock P. (1999). Eur. J. Gastroenterol. Hepatol. 11: 267
276. Cited from Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl. Microbiol.
104: 305-344.
98. Yasui H, Nagaoka N, Mike A, Hayakawa K and Ohwaki M. (1991). Microb. Ecol. Hlth.
Dis. 5: 155162. Cited from Macfarlane G T, Steed H and Macfarlane S. (2008). J. Appl.
Microbiol. 104: 305 - 344.
... GOS are synthesized from lactose through a transgalactosylation reaction catalyzed by an enzyme -galactosidase. [3][4][5] GOS provide their health benefits by two main mechanisms: first by selective proliferation of bifidobacteria and lactobacilli in the guts, which provide resistance against colonization of pathogens there by reducing infections and second mechanism by production of short fatty acids, which reduces the risk of cancer, increases mineral absorption, and controls serum lipid and cholesterol levels. 1,2 . ...
Article
Full-text available
Galactooligosaccharides (GOS) used as prebiotics are one of the major constituents of the infant milk formulas. GOS (Gossence™) is produced by a patented process of biotransformation of lactose; hence toxicology studies were carried out to assess its safety. The objective of the present study was to evaluate the general and genetic toxicity of Gossence™. In 14-day and subchronic (90-day) oral toxicity studies in Sprague Dawley rats, daily administration of GOS at dose levels of 1000, 2000, or 5000 mg/kg (equivalent to 1347, 2694, and 6735 mg/kg/day of Gossence™, respectively) did not cause any mortality, or clinical signs, and changes in body weights, feed consumption, hematology, clinical chemistry, and urinalysis. In 90-day study, no changes in ophthalmological and neurological findings were observed. Significant increases in the cecum weights (with and/or without content) at dose levels of ≥2000 mg/kg were observed in both 14-day and 90-day studies. Based on the results of 90-day study, the no-observed-adverse-effect-level for GOS is 5000 mg/kg/day which is equivalent to 6735 mg Gossence™/kg/day. In the bacterial reverse mutation test, there was no significant increase in the mean numbers of revertants at the tested concentrations. Gossence™ was not mutagenic up to 5000 µg/plate. In chromosomal aberration test, there was no statistically significant increase in the number of percent aberrant metaphase for the Gossence™. Gossence™ is non-clastogenic (negative) in the in vitro chromosomal aberration test using human peripheral blood lymphocyte during short and prolonged treatment.
Article
Full-text available
Transgalactosylation reaction is the penultimate step in the production of galactooligosaccharides (GOSs) which has prominent applications in the treatment of disorders. In the present study, partially purified β-galactosidase from Enterobacter aerogenes KCTC2190 was used for the synthesis of prebiotic GOSs. GOSs were produced using lactose as substrate. Structural elucidation of collected fractions of GOSs by liquid chromatography electrospray ionization mass spectrometry exhibited the appearance of major peaks of produced GOSs at m/z 241.20, 481.39, 365.11, 527.17, and 701.51 respectively. GOSs facilitated the growth of potential probiotic strains (Lactobacillus delbrueckii ssp. helveticus, Bifidobacterium bifidum, and Lactiplantibacillus plantarum) and liberated propionate and butyrate as principal short-chain fatty acids which established its prebiotic potency. Synbiotic combinations exhibited good antioxidant activities. Synbiotic combinations also exhibited antimicrobial activities against pathogenic microorganisms namely Staphylococcus aureus and Escherichia coli. Synbiotic combinations of GOSs and the respective probiotic microorganisms were able to decrease viable human bone cancer cells (MG-63).
Article
Full-text available
The effects of galacto-oligosaccharides (GOS), Yucca schidigera (YS) or nisin (NS), as additives to a basal diet of grass silage and concentrate, on rumen methanogenesis, nitrogen and energy metabolism were conducted using four rumen cannulated wethers in a 4×4 Latin square design. Four treatments comprised basal diet (control), basal diet+20 g GOS, basal diet+120 ppm YS, basal diet+3 mg/kg BW0.75 of NS. Apparent digestibility of DM, OM, CP, NDF and ADF were similar in all treatment diets. Animals fed YS had lower N losses in urine and total N losses resulting in a higher retained N. Ruminal pH values ranged from 6.33 to 6.47 and was significantly (P<0.05) altered by treatment. Sheep given YS had the lowest NH3–N concentration, moderate in control and GOS, and the highest in NS. The GOS supplemented sheep had lower (P<0.01) proportion of acetic acid and higher (P<0.01) proportion of propionic acid compared to those fed the control diet. Microbial nitrogen supply was higher (P<0.05) in GOS supplemented sheep than those given control, YS and NS diets. Relative to control, YS and NS treatments, GOS reduced (P<0.05) methane production (l/kg BW0.75). These results indicated that natural products have the potential to be used as manipulators of rumen fermentation.
Article
Full-text available
Butyrate slows the growth of cancer cells cultured in vitro. To determine the relevance of the fermentative production of butyrate in vivo, colonic butyrate concentrations were manipulated by feeding different dietary fibres and were related to tumour development in the rat dimethylhydrazine model of large bowel cancer. It has previously been shown that guar gum and oat bran, while highly fermentable, are associated with low butyrate levels in the distal colon, while wheat bran causes significantly higher concentrations. Diets containing these fibres (nominally 10% w:w) were administered for 3 weeks before, for 10 weeks during, and for 20 weeks after dimethylhydrazine administration, after which animals were killed and examined for tumours. Significantly fewer tumours were seen in the rats fed wheat bran compared with those fed guar or oat bran, and the total tumour mass was lowest in rats fed wheat bran. Rats on a 'no added fibre diet' had an intermediate tumour mass. Regression analysis, performed regardless of dietary group, showed that the concentration in stools of butyrate but not of acetate or stool volume, correlated significantly (and negatively) with tumour mass. These findings indicate that fibre which is associated with high butyrate concentrations in the distal large bowel is protective against large bowel cancer, while soluble fibres that do not raise distal butyrate concentrations, are not protective. Thus, butyrate production in vivo does bear a significant relationship to suppression of tumour formation.
Article
Synthesis of prebiotic α- and β-galactooligosaccharides (GOS) using the whole cells of Bifidobacterium bifidum NCIMB 41171 was investigated. Determination of α- and β-galactosidase activities showed them to be at 3 and 205 U g−1 of freeze dried biomass, respectively, and they increased to 5 and 344 U g−1, respectively, when cells were treated with toluene. Starting with 450–500 mg mL−1 lactose, maximum GOS concentrations were observed at 80–85% lactose conversions and the mixtures contained oligosaccharides (with a degree of polymerisation ⩾3) at 77–109 mg mL−1 and trans-galactosylated disaccharides between 85–115 mg mL−1. The GOS yield values varied between 36% and 43%. An α-linked disaccharide was detected and its presence was confirmed by gas chromatography mass spectroscopy. Cells were re-used up to 8 times without changes in reaction times or the substrate conversions to GOS. Oligosaccharide synthesis was not inhibited by the presence of glucose or galactose. The mixtures were successfully purified from glucose (92% of glucose removed) by fermentation with Saccharomyces cerevisiae with no losses in the oligosaccharide content and only a small decrease on the galactose.
Article
The effect of low-dose inulin consumption on fecal bifidobacteria growth, microbial activity, and tolerance in healthy adults was investigated in a double-blind, randomized, placebo-controlled, parallel-group study. Thirty-nine healthy volunteers were randomly assigned to 2 groups and ingested 2.5 g inulin or placebo twice a day for 4 weeks (from week 2 to week 6). Fresh stools were collected after 2, 4, 6, and 8 weeks for fecal bacteria count and fecal bacterial enzymatic activity measurement. Tolerance was evaluated from a daily chart. In the inulin group, fecal bifidobacteria count increased (P < .0001), whereas no change was observed in the placebo group. Lactobacillus counts did not change in the inulin group and decreased in the placebo group (P = .0004). In the inulin group, a decrease in β-glucuronidase activity (P = .001) was found, which was negatively correlated with the level of Bifidobacterium (P = .04). Throughout the study, there was no change in fecal enterobacteria, pH, β-galactosidase activity, reductase activity, or short-chain fatty acid level in either of the groups. Excess flatus significantly increased in both groups (inulin, P < .0001; placebo, P = .03), but its intensity was very mild. Even at doses as low as 2.5 g twice a day, inulin can exert a prebiotic effect in healthy volunteers by stimulating bifidobacteria growth.
Article
Amyotrophic lateral sclerosis (ALS) is a progressive and devastating neurodegenerative disease caused by selective degeneration and death of motor neurons. So far there are very limited therapeutic options emerged to treat this fatal disease. Homocysteine (Hcy) lowering drugs have been suggested to be a palliative therapy of this disease. Folate, VitaminB12 (VitB12) and VitaminB6 (VitB6) are important elements involved in the Hcy metabolism and we proposed that medications which could promote the absorption of folate, VitB12 and VitB6 might have benefit for ALS. Galactooligosacchrides (GOS) is a prebiotics which could significantly improve the absorption and syntheses of B Vitamins. To investigate whether GOS could provide neuroprotective effect in ALS, we applied GOS and GOS-rich prebiotics yogurt in SOD1(G93A) mice and assessed their effects on disease progression of ALS. Our results showed that GOS and prebiotics yogurt administration significantly delayed the disease onset and prolonged the lifespan in SOD1(G93A) mice. Also, these products increased the concentration of folate, VitB12 and reduced the level of Hcy. Moreover, we found that both GOS and prebiotics yogurt attenuated motor neurons loss, improved the atrophy and mitochondrial activity in myocyte. Furthermore, we demonstrated that GOS and GOS-rich prebiotics treatment suppressed the activation of astrocyte and microglia and regulated several inflammatory- and apoptosis-related factors. Our findings suggested that GOS might have therapeutic potential for ALS, and GOS-rich prebiotics yogurt might be considered as a nutritional therapy for this disease.
Article
Metabolic syndrome is a set of disorders that increases the risk of developing cardiovascular disease. The gut microbiota is altered toward a less beneficial composition in overweight adults and this change can be accompanied by inflammation. Prebiotics such as galactooligosaccharides can positively modify the gut microbiota and immune system; some may also reduce blood lipids. We assessed the effect of a galactooligosaccharide mixture [Bi(2)muno (B-GOS)] on markers of metabolic syndrome, gut microbiota, and immune function in 45 overweight adults with ≥3 risk factors associated with metabolic syndrome in a double-blind, randomized, placebo (maltodextrin)-controlled, crossover study (with a 4-wk wash-out period between interventions). Whole blood, saliva, feces, and anthropometric measurements were taken at the beginning, wk 6, and end of each 12-wk intervention period. Predominant groups of fecal bacteria were quantified and full blood count, markers of inflammation and lipid metabolism, insulin, and glucose were measured. B-GOS increased the number of fecal bifidobacteria at the expense of less desirable groups of bacteria. Increases in fecal secretory IgA and decreases in fecal calprotectin, plasma C-reactive protein, insulin, total cholesterol (TC), TG, and the TC:HDL cholesterol ratio were also observed. Administration of B-GOS to overweight adults resulted in positive effects on the composition of the gut microbiota, the immune response, and insulin, TC, and TG concentrations. B-GOS may be a useful candidate for the enhancement of gastrointestinal health, immune function, and the reduction of metabolic syndrome risk factors in overweight adults.
Article
This work established a quantitative score to describe the extent to which prebiotics (fructooligosaccharides, inulin, and galactooligosaccharides) support selective growth of lactobacilli and bifidobacteria. The prebiotic activity assay was based on the change in cell biomass after 24 h of growth of the probiotic strain on 1% prebiotic or 1% glucose relative to the change in cell biomass of a mixture of enteric strains grown under the same conditions. From the biomass data, a prebiotic activity score was calculated for five lactobacilli and five bifidobacteria. In general, the scores were dependent on the probiotic bacterial strain tested and the type of prebiotic carbohydrate utilized. The highest score was obtained for Lactobacillus paracasei 1195 grown on inulin (1.17), and the lowest score was for Bifidobacterium bifidum NCI grown on galactooligosaccharides (−1.24). Results reported here provide a basis for evaluating and optimizing combinations of probiotics and prebiotics for applications as synbiotics.
Article
Gut microflora-mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (IBS). To investigate the efficacy of a novel prebiotic trans-galactooligosaccharide in changing the colonic microflora and improve the symptoms in IBS sufferers. In all, 44 patients with Rome II positive IBS completed a 12-week single centre parallel crossover controlled clinical trial. Patients were randomized to receive either 3.5 g/d prebiotic, 7 g/d prebiotic or 7 g/d placebo. IBS symptoms were monitored weekly and scored according to a 7-point Likert scale. Changes in faecal microflora, stool frequency and form (Bristol stool scale) subjective global assessment (SGA), anxiety and depression and QOL scores were also monitored. The prebiotic significantly enhanced faecal bifidobacteria (3.5 g/d P < 0.005; 7 g/d P < 0.001). Placebo was without effect on the clinical parameters monitored, while the prebiotic at 3.5 g/d significantly changed stool consistency (P < 0.05), improved flatulence (P < 0.05) bloating (P < 0.05), composite score of symptoms (P < 0.05) and SGA (P < 0.05). The prebiotic at 7 g/d significantly improved SGA (P < 0.05) and anxiety scores (P < 0.05). The galactooligosaccharide acted as a prebiotic in specifically stimulating gut bifidobacteria in IBS patients and is effective in alleviating symptoms. These findings suggest that the prebiotic has potential as a therapeutic agent in IBS.